Date: 2011-01-17

Type of information: Development agreement

Compound: metabotropic glutamatereceptor 4 (mGluR4) Positive Allosteric Modulator (PAM) drugs

Company: Domain Therapeutics (France) Merck Serono (Germany)

Therapeutic area: Neurodegenerative diseases - CNS diseases

Type agreement:


Action mechanism:

mGluR4 is a glutamate receptor, member of the G-Protein Coupled Receptor (GPCR)family and is believed to be a potential therapeutic target for Parkinson’s disease.Allosteric modulation of mGluR4 receptors is thought to exert regulatory activity onglutamate-mediated neurotransmission.

Disease: Parkinson’s disease and other neurodegenerative diseases


Domain Therapeutics has concluded an exclusive development and licensing agreement with Merck Serono, to develop metabotropic glutamate receptor 4 (mGluR4) Positive Allosteric Modulator (PAM) drugs targeting Parkinson’s disease and other neurodegenerative diseases. Domain Therapeutics will contribute optimized compounds that have been developed from its proprietary chemical series.

Financial terms:

Under the terms of the agreement, Domain Therapeutics will receive € 2 million in upfront payment and research funding, and is eligible for up to €132 million in milestones for the first two products, as well as undisclosed royalties.

Latest news:

Is general: Yes